News

According to the companies’ collaboration agreement, Schering-Plough is responsible for further development of the compounds. Pharmacopeia is eligible to receive milestone payments if the program advances into late-stage

The application was submitted to the Japanese Ministry of Health, Labour and Welfare (MHLW) by Chugai Pharmaceutical, a Japanese affiliate to Roche, OSI’s international partner for Tarceva (erlotinib).

The proceeds will be used primarily to fund PharmaFrontiers’ phase IIb trial with Tovaxin for the treatment of multiple sclerosis. The company expects to begin the trial in

The changes include a reduction in the number of total patients to be enrolled from 300 down to 243, as well as an increase in the randomization ratio

In the study, named STAR, both Evista (raloxifene) and tamoxifen reduced the risk of developing invasive breast cancer by about 50%. In addition, within the study, women who

One of the patents claims use of immune system modulation to remove proteins associated with Alzheimer’s disease (AD), while the other, unrelated, patent relates to the isolation and

Acambis submitted the application on a rolling basis, starting with the first portion in January 2006. The BLA includes safety, tolerability and immunogenicity data obtained from clinical trials

Cytokinetics is conducting this clinical trial in order to expand the development activities for SB-743921, based on a recently amended agreement with GlaxoSmithKline. SB-743921 is the second drug

Ortec is a tissue-engineering company involved in the commercialization of a proprietary and patented technology to stimulate the repair and regeneration of human tissue. Hapto Biotech, meanwhile, is